Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2022 08:05 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study

ENGLEWOOD CLIFFS, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
October 18, 2022 07:15 ET | Source: Silo Pharma, Inc.

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety Therapeutics

ENGLEWOOD CLIFFS, NJ, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
October 10, 2022 08:05 ET | Source: Silo Pharma, Inc.

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Studies of SP-26, the company’s proprietary, time-released ketamine show positive results in reducing neuropathic nerve pain ENGLEWOOD CLIFFS, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Silo...
October 06, 2022 08:20 ET | Source: Silo Pharma, Inc.

Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12

Presentation to feature Company’s novel therapeutic candidates under development in collaboration with leading academic institutions ENGLEWOOD CLIFFS, NJ, Oct. 06, 2022 (GLOBE NEWSWIRE) --...
October 03, 2022 09:47 ET | Source: Silo Pharma, Inc.

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine ENGLEWOOD CLIFFS, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the...
September 30, 2022 08:30 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

ENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...
September 27, 2022 09:05 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock

ENGLEWOOD CLIFFS, NJ , Sept. 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional...
September 15, 2022 08:00 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces Implementation of 1-for-50 Reverse Stock Split in Preparation for Planned Uplisting to Nasdaq

ENGLEWOOD CLIFFS, NJ , Sept. 15, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics...
July 27, 2022 08:15 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma,...
July 12, 2022 11:23 ET | Source: Silo Pharma, Inc.

Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients

ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right